- Business Wire•2 days agoAlnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today initial data from its ongoing Phase 1/2 study with ALN-GO1, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1 .
- Motley Fool•2 days ago
Both of these clinical-stage biotechs are big losers in 2016 so far. Which has the better chance of becoming a winner?
- Business Wire•5 days ago
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced that it has granted stock options to Yvonne Greenstreet, the Company's newly appointed Chief Operating Officer.
Alnylam Pharmaceuticals, Inc. (ALNY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||76.00 x 100|
|Ask||86.12 x 300|
|Day's Range||75.31 - 77.25|
|52wk Range||49.96 - 110.75|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-17.93|
|Avg Vol (3m)||682,850|
|Dividend & Yield||N/A (N/A)|